| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8733495 | Acta Haematologica Polonica | 2017 | 8 Pages |
Abstract
Ibrutinib is characterized by high clinical efficacy and acceptable toxicity in CLL patients with 17p deletion in daily clinical practice.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Bartosz PuÅa, Elżbieta Iskierka-Jażdżewska, Marek Hus, Agnieszka Szymczyk, Aleksandra GoÅos, Magdalena Piotrowska, Daria Zawirska, Jan Maciej Zaucha, PaweÅ Steckiewicz, Marcin Pasiarski, Dominik Chraniuk, Weronika Piszczek, MichaÅ Osowiecki,